Tags

Type your tag names separated by a space and hit enter

SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines.
J Biol Regul Homeost Agents. 2020 06 01; 34(3)JB

Abstract

Acute severe respiratory syndrome coronavirus-2 (SARS-CoV-2) caused a global pandemic coronavirus disease 2019 (COVID-19). In humans, SARS-CoV-2 infection leads to acute respiratory distress syndrome which presents edema, hemorrhage, intra-alveolar fibrin deposition, and vascular changes characterized by thrombus formation, micro-angiopathy and thrombosis. These clinical signs are mediated by pro-inflammatory cytokines. In recent studies it has been noted that COVID-19 pandemic can affect patients of all ages, including children (even if less severely) who were initially thought to be immune. Kawasaki disease is an autoimmune acute febrile inflammatory condition, which primarily affects young children. The disease can present immunodeficiency with the inability of the immune system to fight inflammatory pathogens and leads to fever, rash, alterations of the mucous membranes, conjunctiva infection, pharyngeal erythema, adenopathy, and inflammation. In the COVID-19 period, virus infection aggravates the condition of Kawasaki disease, but it has also been noted that children affected by SARS-V-2 may develop a disease similar to Kawasaki's illness. However, it is uncertain whether the virus alone can give Kawasaki disease-like forms. As in COVID-19, Kawasaki disease and its similar forms are mediated by pro-inflammatory cytokines produced by innate immunity cells such as macrophages and mast cells (MCs). In light of the above, it is therefore pertinent to think that by blocking pro-inflammatory cytokines with new anti-inflammatory cytokines, such as IL-37 and IL-38, it is possible to alleviate the symptoms of the disease and have a new available therapeutic tool. However, since Kawasaki and Kawasaki-like diseases present immunodeficiency, treatment with anti-inflammatory/immunosuppressant molecules must be applied very carefully.

Authors+Show Affiliations

Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.Specialization School in Oral Surgery, Vita-Salute San Raffaele University, Milan, Italy.Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.School of Pharmacy, University of Camerino, Camerino, Italy.University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA.Postgraduate Medical School, University of Chieti, Chieti, Italy.

Pub Type(s)

Editorial

Language

eng

PubMed ID

32476380

Citation

Ronconi, G, et al. "SARS-CoV-2, Which Induces COVID-19, Causes Kawasaki-like Disease in Children: Role of Pro-inflammatory and Anti-inflammatory Cytokines." Journal of Biological Regulators and Homeostatic Agents, vol. 34, no. 3, 2020.
Ronconi G, Teté G, Kritas SK, et al. SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines. J Biol Regul Homeost Agents. 2020;34(3).
Ronconi, G., Teté, G., Kritas, S. K., Gallenga, C. E., Caraffa, A. l., Ross, R., & Conti, P. (2020). SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines. Journal of Biological Regulators and Homeostatic Agents, 34(3). https://doi.org/10.23812/EDITORIAL-RONCONI-E-59
Ronconi G, et al. SARS-CoV-2, Which Induces COVID-19, Causes Kawasaki-like Disease in Children: Role of Pro-inflammatory and Anti-inflammatory Cytokines. J Biol Regul Homeost Agents. 2020 06 1;34(3) PubMed PMID: 32476380.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - SARS-CoV-2, which induces COVID-19, causes kawasaki-like disease in children: role of pro-inflammatory and anti-inflammatory cytokines. AU - Ronconi,G, AU - Teté,G, AU - Kritas,S K, AU - Gallenga,C E, AU - Caraffa,Al, AU - Ross,R, AU - Conti,P, Y1 - 2020/06/01/ PY - 2020/6/2/entrez PY - 2020/6/2/pubmed PY - 2020/6/2/medline KW - COVID-19 KW - Kawasaki KW - SARS-CoV-2 KW - anti-inflammatory KW - cytokines KW - immunity KW - immunodeficiency KW - inflammation KW - virus JF - Journal of biological regulators and homeostatic agents JO - J. Biol. Regul. Homeost. Agents VL - 34 IS - 3 N2 - Acute severe respiratory syndrome coronavirus-2 (SARS-CoV-2) caused a global pandemic coronavirus disease 2019 (COVID-19). In humans, SARS-CoV-2 infection leads to acute respiratory distress syndrome which presents edema, hemorrhage, intra-alveolar fibrin deposition, and vascular changes characterized by thrombus formation, micro-angiopathy and thrombosis. These clinical signs are mediated by pro-inflammatory cytokines. In recent studies it has been noted that COVID-19 pandemic can affect patients of all ages, including children (even if less severely) who were initially thought to be immune. Kawasaki disease is an autoimmune acute febrile inflammatory condition, which primarily affects young children. The disease can present immunodeficiency with the inability of the immune system to fight inflammatory pathogens and leads to fever, rash, alterations of the mucous membranes, conjunctiva infection, pharyngeal erythema, adenopathy, and inflammation. In the COVID-19 period, virus infection aggravates the condition of Kawasaki disease, but it has also been noted that children affected by SARS-V-2 may develop a disease similar to Kawasaki's illness. However, it is uncertain whether the virus alone can give Kawasaki disease-like forms. As in COVID-19, Kawasaki disease and its similar forms are mediated by pro-inflammatory cytokines produced by innate immunity cells such as macrophages and mast cells (MCs). In light of the above, it is therefore pertinent to think that by blocking pro-inflammatory cytokines with new anti-inflammatory cytokines, such as IL-37 and IL-38, it is possible to alleviate the symptoms of the disease and have a new available therapeutic tool. However, since Kawasaki and Kawasaki-like diseases present immunodeficiency, treatment with anti-inflammatory/immunosuppressant molecules must be applied very carefully. SN - 0393-974X UR - https://www.unboundmedicine.com/medline/citation/32476380/SARS_CoV_2_which_induces_COVID_19_causes_kawasaki_like_disease_in_children:_role_of_pro_inflammatory_and_anti_inflammatory_cytokines_ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.